Skip to content

Novavax NVAX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Moderna logo
ModernaMRNA
Roivant Sciences logo
Roivant SciencesROIV
Merck & Co. logo
Merck & Co.MRK
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's deferred tax assets and other non-current assets?
Novavax (NVAX) reported deferred tax assets and other non-current assets of $15.95M in Q1 2026.
How has Novavax's deferred tax assets and other non-current assets changed year-over-year?
Novavax's deferred tax assets and other non-current assets decreased by 27.2% year-over-year, from $21.9M to $15.95M.
What is the long-term trend for Novavax's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Novavax's deferred tax assets and other non-current assets has grown at a 5.3% compound annual growth rate (CAGR), from $13.22M to $17.08M.